UBS initiated coverage of American Healthcare REIT (AHR) with a Buy rating and $51 price target The company is facing a decade of “robust” adjusted funds from operations growth that deserves a premium valuation, the analyst tells investors in a research note. The firm sees upside to 2026 and 2027 consensus estimates, driven by greater than expected acquisition volume pushing American Healthcare’s senior housing operating portfolio exposure higher.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AHR:
- Buy Rating for American Healthcare REIT, Inc. Driven by Strong AFFO Growth and Strategic Expansion in Senior Housing
- American Healthcare REIT Announces Quarterly Distribution
- American Healthcare REIT price target raised to $48 from $45 at Morgan Stanley
- American Healthcare REIT price target raised to $47 from $42 at Scotiabank
- American Healthcare REIT price target raised to $46 from $44 at Truist